HomeCompareLSIHF vs ABBV

LSIHF vs ABBV: Dividend Comparison 2026

LSIHF yields 3333.33% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LSIHF wins by $94.94M in total portfolio value
10 years
LSIHF
LSIHF
● Live price
3333.33%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95.04M
Annual income
$1,547,071.13
Full LSIHF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — LSIHF vs ABBV

📍 LSIHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLSIHFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LSIHF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LSIHF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LSIHF
Annual income on $10K today (after 15% tax)
$283,333.33/yr
After 10yr DRIP, annual income (after tax)
$1,315,010.46/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, LSIHF beats the other by $1,293,954.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LSIHF + ABBV for your $10,000?

LSIHF: 50%ABBV: 50%
100% ABBV50/50100% LSIHF
Portfolio after 10yr
$47.57M
Annual income
$785,921.44/yr
Blended yield
1.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LSIHF
No analyst data
Altman Z
0.3
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LSIHF buys
0
ABBV buys
0
No recent congressional trades found for LSIHF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLSIHFABBV
Forward yield3333.33%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$95.04M$102.3K
Annual income after 10y$1,547,071.13$24,771.77
Total dividends collected$69.99M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LSIHF vs ABBV ($10,000, DRIP)

YearLSIHF PortfolioLSIHF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$177,367$166,666.67$11,550$430.00+$165.8KLSIHF
2$1,571,143$1,381,360.33$13,472$627.96+$1.56MLSIHF
3$7,399,026$5,717,903.55$15,906$926.08+$7.38MLSIHF
4$20,499,894$12,582,936.21$19,071$1,382.55+$20.48MLSIHF
5$38,225,794$16,290,907.46$23,302$2,095.81+$38.20MLSIHF
6$55,096,633$14,195,032.83$29,150$3,237.93+$55.07MLSIHF
7$68,514,130$9,560,732.50$37,536$5,121.41+$68.48MLSIHF
8$78,865,738$5,555,619.33$50,079$8,338.38+$78.82MLSIHF
9$87,374,658$2,988,318.85$69,753$14,065.80+$87.30MLSIHF
10$95,037,956$1,547,071.13$102,337$24,771.77+$94.94MLSIHF

LSIHF vs ABBV: Complete Analysis 2026

LSIHFStock

Lai Sun Garment (International) Limited, an investment holding company, invests in and develops properties in Hong Kong, the United Kingdom, Vietnam, Mainland China, Macau, and internationally. The company operates through Property Development and Sales, Property Investment, Hotel Operation, Restaurant and F&B Product Sales Operations, Media and Entertainment, Film and TV Program, Cinema Operation, Theme Park Operation, and Other segments. Its property portfolio includes commercial/retail, office, industrial, residential, and hotel/serviced apartment properties. The company also invests in, develops, operates, and manages hotels and restaurants, cultural, leisure, entertainment, and related facilities; and invests in, produces, licenses, distributes, and sells television programs, films, and video format products, as well as engages in the golf apparel retailing. In addition, it provides management and consultancy services to hotels, restaurants, and serviced apartments; property management, real estate agency, performance agency, leasing agency, and building services; luxury yachts brokerage, charter, marketing, management, and crew placement services; finance and treasury services; and artiste management services. Further, the company engages in the development, operation, and investment of media, entertainment, and music production and distribution; and cinema operations, as well as provides related advertising services. Additionally, it sells albums and beverage products; distributes and licenses music; trades in gaming products; and develops and operates theme parks. Furthermore, the company is involved in the film library management, central kitchen operation, and video duplication services, as well as translating and subtitling of television programs. Lai Sun Garment (International) Limited was founded in 1947 and is headquartered in Central, Hong Kong.

Full LSIHF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LSIHF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LSIHF vs SCHDLSIHF vs JEPILSIHF vs OLSIHF vs KOLSIHF vs MAINLSIHF vs JNJLSIHF vs MRKLSIHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.